Literature DB >> 29566217

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

M E Lacouture1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29566217      PMCID： PMC5913626          DOI： 10.1093/annonc/mdy084

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  15 in total

1.  A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.

Authors:  Viswanath R Belum; Michael A Marchetti; Stephen W Dusza; Andrea Cercek; Nancy E Kemeny; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2017-09       Impact factor: 11.527

2.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.

Authors:  Mario E Lacouture; Edith P Mitchell; Bilal Piperdi; Madhavan V Pillai; Heather Shearer; Nicholas Iannotti; Feng Xu; Mohamed Yassine
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

Review 3.  Mechanisms of cutaneous toxicities to EGFR inhibitors.

Authors:  Mario E Lacouture
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

4.  Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.

Authors:  Smita S Joshi; Sara Ortiz; Joslyn N Witherspoon; Alfred Rademaker; Dennis P West; Roger Anderson; Sara E Rosenbaum; Mario E Lacouture
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

5.  Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.

Authors:  R E Eilers; M Gandhi; J D Patel; M F Mulcahy; M Agulnik; T Hensing; Mario E Lacouture
Journal:  J Natl Cancer Inst       Date:  2009-12-09       Impact factor: 13.506

6.  Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.

Authors:  Barbara Melosky; Helen Anderson; Ronald L Burkes; Quincy Chu; Desiree Hao; Vincent Ho; Cheryl Ho; Wendy Lam; Christopher W Lee; Natasha B Leighl; Nevin Murray; Sophie Sun; Robert Winston; Janessa J Laskin
Journal:  J Clin Oncol       Date:  2015-11-16       Impact factor: 44.544

7.  Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.

Authors:  Susan L Boone; Alfred Rademaker; Dachao Liu; Carmen Pfeiffer; David J Mauro; Mario E Lacouture
Journal:  Oncology       Date:  2007-12-21       Impact factor: 2.935

8.  Activation of ErbB2 by 2-methyl-1,4-naphthoquinone (menadione) in human keratinocytes: role of EGFR and protein tyrosine phosphatases.

Authors:  Juliane I Beier; Claudia von Montfort; Helmut Sies; Lars-Oliver Klotz
Journal:  FEBS Lett       Date:  2006-02-28       Impact factor: 4.124

9.  A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.

Authors:  Andreas Wollenberg; Nicolas Moosmann; Elisabeth Klein; Kerstin Katzer
Journal:  Exp Dermatol       Date:  2008-05-22       Impact factor: 3.960

10.  Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.

Authors:  Alon Scope; Anna Liza C Agero; Stephen W Dusza; Patricia L Myskowski; Jocelyn A Lieb; Leonard Saltz; Nancy E Kemeny; Allan C Halpern
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.